FCAR/CD89 Antibody [Unconjugated]

Human whole blood monocytes and granulocytes were stained with Sheep Anti-Human FCAR/CD89 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF3939, filled histogram) or isotype control antibody (Catalog # 5-001-A, open histogram), followed by NorthernLights™ 557-conjugated Anti-Sheep IgG Secondary Antibody (Catalog # NL010).

• Reactivity: Hu
• Applications: WB, Flow, CyTOF-ready
• Clonality: Polyclonal
• Host: Sheep
• Conjugate: Unconjugated
• Concentration: LYOPH

FCAR/CD89 Antibody [Unconjugated] Summary

• Immunogen: Mouse myeloma cell line NS0-derived recombinant human FCAR/CD89
  Gln22-Asn227
  Accession # P24071
• Specificity: Detects human FCAR/CD89 in direct ELISAs and Western blots. In direct ELISAs and Western blots, less than 1% cross‑reactivity with recombinant human (rh) Fc gamma R1 alpha , rhFc gamma R2 alpha , and rhFc gamma R3 beta is observed.
• Source: N/A
• Isotype: IgG
• Clonality: Polyclonal
• Host: Sheep
• Gene: FCAR
• Purity Statement: Antigen Affinity-purified

Applications/Dilutions

• Dilutions:
  • CyTOF-ready
  • Flow Cytometry 0.25 ug/10^6 cells
  • Western Blot 0.1 ug/mL

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.
• Preservative: No Preservative
• Concentration: LYOPH
• Reconstitution Instructions: Reconstitute at 0.2 mg/mL in sterile PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for FCAR/CD89 Antibody [Unconjugated]

• CD89 antigen
• CD89
• CD89IgA Fc receptor
• Fc alpha receptor
• Fc fragment of IgA, receptor for
• FCAR
• immunoglobulin alpha Fc receptor

Background

FCAR, also called Fc alpha RI or CD89, is a variably glycosylated 50‑100 kDa myeloid-specific type I transmembrane (TM) Fc receptor for IgA that is a member of the multichain immune recognition receptor (MIRR) family (1‑3). Human FCAR contains a 21 amino acid (aa) signal sequence and extracellular (ECD), TM and cytoplasmic domains of 206, 19 and 41 aa, respectively (4). Arg230 within the TM domain supports interaction with the ITAM-containing signaling subunit, FcR gamma , which contains a TM Asp (5‑7). Two ECD C2-type Ig-like domains (EC1 and 2) are oriented at right angles (8). Up to two molecules of FCAR can bind one molecule of serum IgA via EC1 (8). Many splice variants have been reported, but only two have been identified as proteins (9, 10). The a.2 form, which lacks 22 aa just prior to the TM domain, is exclusively expressed in alveolar macrophages. The a.3 form lacks EC2. FCAR binds monomeric, polymeric and secretory IgA, but does not mediate the barrier function of secretory IgA in mucosal epithelium (1‑3). Shedding and circulation of polymeric IgA/FCAR immune complexes has been reported (11). Circulating neutrophils, eosinophils, and monocytes express FCAR (12). Tissue expression of FCAR is mainly from neutrophils; FCAR is downregulated as monocytes differentiate to tissue macrophages (12). On neutrophils, a significant amount of FCAR lacks FcR gamma , but can still be endocytosed to early endosomes and recycled to the cell surface (5). Binding of serum IgA to FCAR is transient and anti-inflammatory, inhibiting IgG or IgE-induced degranulation (6). Sustained aggregation of FCAR results in inflammatory responses (6). FcR gamma signaling is required for these and for transport to late endosomes (5 - 7). Human FCAR shows 55‑58% aa identity with rat, horse and cow FCAR. No ortholog occurs in mouse. FCAR structure resembles the KIR/ILT/LIR/MIR family more than other IgA receptors, including pIgR, Fc alpha /μR, asialoglycoprotein receptor (ASGR1) and transferrin receptor (TfR) (1‑3).

1. Wines, B. D. and P. M. Hogarth (2006) Tissue Antigens 68:103.
2. Otten, M. A. and M. van Egmon (2004) Immunol. Lett. 92:23.
3. Montiero, R. C. and J. G. J. van de Winkel (2003) Annu. Rev. Immunol. 21:177.
4. Maliszewski, C. R. et al. (1990) J. Exp. Med. 172:1665.
5. Launay, P. et al. (1999) J. Biol. Chem. 274:7216.
6. Pasquier, B. et al. (2005) Immunity 22:31.
7. Shen, L. et al. (2001) Blood 97:205.
8. Herr, Y. et al. (2003) Nature 423:614.
9. Patry, C. et al. (1996) J. Immunol. 156:4442.
10. Togo, S. et al. (2003) FEBS Lett. 535:205.
11. van der Boog, P. J. M. et al. (2002) J. Immunol. 168:1252.
12. Hamre, R. et al. (2003) Scand. J. Immunol. 57:506.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Bioinformatics

• Gene Symbol: FCAR
• Uniprot:
  • P24071()